WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced that on the day after launch it had exceeded its Quell pre-order thirty day campaign goal. The Company reported preorders for over 500 Quell devices. Demand exceeded company projections and the initial offer sold out in less than 6-hours. The campaign was launched Monday on Indiegogo, the world’s largest crowdfunding platform. The campaign that runs through April 1, was developed to gauge consumer interest in Quell before it is launched later this year. The NeuroMetrix campaign can be found at: Quell Indiegogo Campaign.
Quell is FDA cleared for treatment of chronic pain without a prescription. It uses NeuroMetrix's proprietary, 100% drug-free, non-invasive neurostimulation technology to provide relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia, and osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy.
Consumers and medical professionals can visit QuellRelief.com to learn more, sign up to receive information, and support the Indiegogo campaign. The company expects to start shipping product in Spring 2015. Quell will initially be available exclusively through doctor's office and online.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. For more information, please visit http://www.NeuroMetrix.com.
